Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire•03/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 net product sales $185.7 million, up from $133.0 million year over year
- ➤2026 net product sales guidance raised to $715 million-$720 million
- ➤ATEBRIOZ approved and launched for FOP patients aged 12 years and older
- ➤Brelovitug AZURE-1 Phase 3 study met its primary endpoint in chronic HDV
- ➤LIVMARLI EXPAND Phase 3 met its primary endpoint and all prespecified secondary endpoints
Expert Statements
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals
“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio.”
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals
“Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals
“Together with continued momentum across our commercial business, these milestones position Mirum for another meaningful inflection with five potential upcoming approvals and label expansions.”
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
- Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million
Get started
Create a free account to read the full story.